Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesBeginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Mangoceuticals (MGRX) Short-Term Debt repayments (2023 - 2024)

Mangoceuticals recorded quarterly Short-Term Debt repayments of -$37500.0 in Q4 2024, down 142.86% quarter-over-quarter from $87500.0 in Q1 2024.

Mangoceuticals' Short-Term Debt repayments history runs 2 years deep, the most recent figure standing at -$37500.0 for Q4 2024.

  • In Q4 2024, Short-Term Debt repayments changed N/A year-over-year to -$37500.0; the TTM figure through Dec 2025 stood at $50000.0 (up 276.93% YoY), while the FY2025 annual figure was $500000.0, up 233.33% from the prior year.
  • Short-Term Debt repayments came in at -$37500.0 for Q4 2024 at Mangoceuticals, down from $87500.0 in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $87500.0 in Q1 2024 to a low of -$78260.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn -
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn -
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn -
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn -
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn -
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn -
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn -
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn -
10 Mangoceuticals 7.03 Mn 6.84 Mn 29,001.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -37,500.00
Dec 31, 2024 -37,500.00
Mar 31, 2024 87,500.00
Mar 31, 2024 87,500.00
Mar 31, 2023 -78,260.00
Mar 31, 2023 -78,260.00